[The effects of human atrial natriuretic peptide on the pediatric recipients of living-related renal transplantation].
We evaluated the effects of human natriuretic peptide (hANP) on the recipients of living-related renal transplantation in children. Anesthesia was maintained with nitrous-oxide and isoflurane in oxygen. The recipients were divided into two groups: the hANP group (n = 8) received continuous infusion of hANP (0.1 microgram.kg-1.min-1), and the control group (n = 5) received no hANP infusion. Intravenous hANP infusion was started at the loading time of fresh frozen plasma in the recipients until the 12 hours after operation. There were no differences between the groups with regards to age, height, body weight, changes in heart rate and systolic arterial pressure, urine volume during operation, and the levels of blood uremic nitrogen and creatinine. The hANP group showed minimal change in CVP during operation and body weight between the values during and after operation compared with control group. The control group needed significantly more fluid than hANP group during operation. We concluded that continuous i.v. hANP infusion in the pediatric recipients of living-related renal transplantation was useful for maintaining sufficient urination and prevention of heart failure or lung edema.
Sasaki
J
J
First Department of Anesthesiology, Toho University School of Medicine, Tokyo.
Yoshida
K
K
Nagasawa
M
M
Kikuchi
H
H
D000768:Anesthesia, General; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D006333:Heart Failure / Q000517:prevention & control; D006801:Humans; D007262:Infusions, Intravenous; D007431:Intraoperative Complications / Q000517:prevention & control; D016030:Kidney Transplantation; D019520:Living Donors; D019990:Perioperative Care; D011654:Pulmonary Edema / Q000517:prevention & control; D014554:Urination
D009320:Atrial Natriuretic Factor